Pharmacologic management of neovascular age-related macular degeneration: Systematic review of economic evidence and primary economic evaluation

Keyphrases

• Acetate 33%
• Analytic Approach 33%
• Article 12 33%
• Bevacizumab 33%
• Canadian Healthcare 33%
• CINAHL 33%
• Clinically Significant 33%
• Cochrane Library 33%
• Cost-utility 33%
• Cost-utility Analysis 33%
• Decision-analytic Model 33%
• Economic Analysis 33%
• Economic Evaluation 100%
• Economic Evidence 100%
• Economic Implications 33%
• Economic Literature 66%
• Embase 33%
• Evaluation Database 33%
• Health Economic Evaluation 33%
• High Cost 33%
• Intravitreal Triamcinolone 33%
• Literature Search 33%
• Macular Laser 33%
• Markov Model 33%
• MEDLINE 33%
• Method Study 33%
• Microsimulation 33%
• Neovascular Age-related Macular Degeneration (nAMD) 100%
• Pegaptanib 66%
• Pharmacologic Management 100%
• Pharmacological Therapy 33%
• Photodynamic Therapy 33%
• Placebo 33%
• PubMed Health 33%
• Quality-adjusted Life Years 66%
• Ranibizumab 100%
• Utility Theory 33%
• Verteporfin 33%
• Wet Age-related Macular Degeneration 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Age Related Macular Degeneration 33%
• Anecortave 33%
• Bevacizumab 33%
• Pegaptanib 66%
• Photodynamic Therapy 33%
• Placebo 33%
• Ranibizumab 100%
• Triamcinolone 33%
• Verteporfin 33%
• Wet Macular Degeneration 100%

Economics, Econometrics and Finance

• Economic Analysis 50%
• Economics of Literature 50%
• Health Economics 50%
• Markov Model 50%
• Systematic Review 100%
• Utility Theory 50%